BMX-001 not checked

BioMimetix JV, LLC · MnTnBuOE-2-PyP5+

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species…”In the company’s words, NCT06620029 on ClinicalTrials.gov
Tested for
Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Main trialPhase 1/2
“This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripheral neuropathy (CIPN) in patients with recurrent ovarian and endometrial cancers, which are among the most lethal gynecologic malignancies worldwide. The study focuses on BMX-001, a redox-active manganese metalloporphyrin compound that uniquely combines the ability to enhance anti-tumor efficacy and protect normal tissues from the toxic effects of chemotherapy, specifically paclitaxel (PTX). PTX, despite being a cornerstone of treatment,…”In the company’s words, NCT06620029 on ClinicalTrials.gov
Other names
manganese butoxyethyl pyridyl porphyrin · MnTnBuOE-2-PyP5+ · Whole Brain Radiation Therapy

Other drugs for Ovarian Neoplasms

All 265 drugs for Ovarian Neoplasms

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 31 Mar 2027 BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
Phase 2Withdrawn Jul 2023 Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
Phase 1/2Completed 21 Feb 2020 A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Phase 1/2Completed 17 Aug 2023 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Phase 1/2Terminated 31 Dec 2023 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BMX-001

Following is part of Solo: you see every change to BMX-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in